Securities code: 688139 securities abbreviation: Qingdao Haier Biomedical Co.Ltd(688139) Announcement No.: 2022-004 Qingdao Haier Biomedical Co.Ltd(688139)
Announcement on the resolution of the fifth meeting of the second board of directors
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
1、 Meetings of the board of directors
The fifth meeting of the second board of directors of Qingdao Haier Biomedical Co.Ltd(688139) (hereinafter referred to as “the company”, “the company” or ” Qingdao Haier Biomedical Co.Ltd(688139) “) was held by on-site combined communication at 10:00 a.m. on February 6, 2022. The on-site meeting was held in the conference room on the 19th floor of Yingkang life building. The notice of this meeting was sent to all directors by e-mail on January 27, 2022. The meeting was presided over by Tan Lixia, the chairman of the board of directors. The convening and convening procedures of the meeting shall comply with the provisions of relevant laws and regulations, normative documents and the articles of association, and the resolutions of the meeting shall be legal and effective.
2、 Deliberations of the board meeting
Tan Lixia, chairman of the board of directors, presided over the meeting. After careful deliberation and voting, the following proposals were adopted at the meeting:
(I) deliberated and passed the proposal on the scheme of repurchasing shares of the company by means of centralized bidding transaction
Based on the confidence in the future development of the company and the recognition of the value of the company, promote the stable, healthy and sustainable development of the company, and agree that the company will use its own funds to repurchase shares through centralized bidding transaction. The repurchased shares will be fully used for employee stock ownership plan or equity incentive at an appropriate time in the future. The repurchased price shall not exceed 100 yuan / share (inclusive), and the total amount of repurchased funds shall not be less than 50 million yuan (inclusive) and not more than 100 million yuan (inclusive); At the same time, the management of the company is authorized to handle matters related to this share repurchase. According to relevant laws and regulations and the relevant provisions of the articles of association, the share repurchase plan does not need to be submitted to the general meeting of shareholders for deliberation.
Voting results: 11 in favor, 0 against and 0 abstention.
The independent directors of the company expressed their independent opinions on this matter.
For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) disclosed by the company on the same day Announcement of Qingdao Haier Biomedical Co.Ltd(688139) on the scheme of repurchasing shares of the company by means of centralized bidding transaction (Announcement No.: 2022-003).
It is hereby announced.
Qingdao Haier Biomedical Co.Ltd(688139) board of directors February 7, 2022
